Inhibitors Product Data Sheet

Blarcamesine • Agonists

Cat. No.: HY-105296 CAS No.: 195615-83-9

Molecular Formula: C₁₉H₂₃NO •

Molecular Weight: 281.39 Screening Libraries Target: Sigma Receptor; mAChR Pathway: GPCR/G Protein; Neuronal Signaling Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description Blarcamesine is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome[1].

IC₅₀ & Target Sigma-1 receptor, muscarinic receptor[1]

In Vivo Blarcamesine (10 mg/kg, 30 mg/kg; p.o.; daily; for 6.5 weeks) ameliorates motor deficits in Mecp2 HET mice with chronic administration[1]. Blarcamesine ameliorates acoustic startle deficit in Mecp2 HET mice[1]. Blarcamesine reverses deficits in visual acuity in older Mecp2 HET mice using the optokinetic response[1]. Blarcamesine produces minimal effects on body weight gain in Mecp2 HET mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female Mecp2tm1.1Bird/J HET (C57 background) mice[1]

Dosage: 10 mg/kg, 30 mg/kg

Administration: Oral administration, daily, for 6.5 weeks

Result: Reverse the deficits observed in the HET animals.

REFERENCES

[1]. Walter E Kaufmann, et al. ANAVEX®2-73 (Blarcamesine), a Sigma-1 Receptor Agonist, Ameliorates Neurologic Impairments in a Mouse Model of Rett Syndrome. Pharmacol Biochem Behav . 2019 Dec;187:172796.

McePdfHeight

Page 1 of 2 www.MedChemExpress.com Caution: Product has not been fully validated for medical applications. For research use only. Tel: 609-228-6898 Fax: 609-228-5909 E-mail: [email protected] Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com